BioMarin FDA Accepts VOXZOGO sNDA for Full Approval
SAN RAFAEL, Calif., July 13, 2026 BioMarin Pharmaceutical Inc. has reached a significant regulatory milestone after the U.S. Food...
BioMarin
Advertisement
BioMarin Reports Positive VOXZOGO and BMN 333 Data at ENDO 2026
SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...
BioMarin Reports Positive Phase 3 VOXZOGO Data in Hypochondroplasia
SAN RAFAEL, Calif., May 20, 2026 BioMarin Pharmaceutical Inc. announced positive topline results from the pivotal Phase 3 CANOPY-HCH-3...
FDA Accepts BioMarin’s PALYNZIQ sBLA for Priority Review in Adolescents with PKU
San Rafael, California — October 30, 2025 — BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration...
Advertisement
